Apollo endosurgery announces positive merit-trial outcomes

Trial results demonstrate esg procedure offers significant and durable weight loss, with improvements in obesity-related health conditions merit-trial met its primary endpoints for safety and efficacy, with patients undergoing the endoscopic sleeve gastroplasty (esg) procedure achieving excess body weight loss of 49.2% at 12 months and a serious adverse event rate of 2% patients undergoing esg also had clinically significant reductions in diabetes, hypertension and metabolic syndrome at 12 months austin, tx / accesswire / october 22, 2021 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that study investigators of the multi-center esg randomized interventional trial (merit) presented positive outcomes. dr. barham abu dayyeh, professor of medicine and director of advanced endoscopy at the mayo clinic, presented the data at the international federation for the surgery of obesity and metabolic disorders (ifso) during the "top 10 papers at ifso" session.
APEN Ratings Summary
APEN Quant Ranking